Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TROMETHAMINE vs PROBALAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tromethamine is a proton acceptor that buffers hydrogen ions, correcting metabolic acidosis by increasing bicarbonate and base excess. It acts as a weak base with high buffering capacity.
Inhibits xanthine oxidase, reducing uric acid production.
Metabolic acidosis associated with cardiac arrest,Correction of metabolic acidosis in acute respiratory acidosis,Metabolic acidosis in renal failure,Metabolic acidosis in diabetes mellitus
Gout,Hyperuricemia,Prevention of tumor lysis syndrome
Intravenous: 1 M solution (3.6 g/30 m L) administered via central line; usual adult dose 300-500 mg/kg (0.27-0.45 g/kg) given over 1-2 hours; may be repeated based on blood gas monitoring.
500 mg orally once daily.
Terminal elimination half-life: 2–3 hours in adults with normal renal function. May be prolonged in renal impairment.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged to 20-40 hours in severe renal impairment (Cr Cl <30 m L/min) requiring dose adjustment.
Tromethamine is not metabolized; it is primarily excreted unchanged by the kidneys.
Primarily hepatic via CYP450; produces active metabolites.
Renal excretion of unchanged drug: >95%. Negligible biliary or fecal elimination.
Primarily renal excretion of unchanged drug (60-70%) via glomerular filtration and tubular secretion; biliary/fecal excretion accounts for 15-25% with the remainder as metabolites.
<10% bound to plasma proteins (albumin).
90-95% bound primarily to albumin and alpha-1-acid glycoprotein.
0.3–0.4 L/kg; primarily distributes in extracellular fluid.
0.15-0.25 L/kg; reflects distribution mainly into extracellular fluid with limited tissue penetration.
Not available (administered intravenously only; oral bioavailability is negligible due to lack of absorption).
Oral: 75-85% (first-pass metabolism reduces absolute bioavailability); Intravenous: 100%.
Contraindicated in anuria or severe renal impairment (GFR < 30 m L/min). Use with caution in renal insufficiency; monitor acid-base balance. No specific dose adjustment guidelines; avoid in renal failure.
Cr Cl 30-50 m L/min: 250 mg daily; Cr Cl <30 m L/min: 125 mg daily; hemodialysis: 125 mg after dialysis.
No specific Child-Pugh based dose adjustments; use with caution in hepatic impairment as metabolism is minimal (primarily renal excretion). Monitor electrolytes and p H.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg daily; Child-Pugh C: not recommended.
Intravenous: 1 M solution; dose based on calculated base deficit: m L of 0.3 M THAM = body weight (kg) × base deficit (m Eq/L) × 1.1. Administer over 1-2 hours via central line. Maximum infusion rate: 5 m L/kg/hour.
10 mg/kg orally once daily, max 500 mg; for children <2 years: 5 mg/kg once daily.
No specific dose adjustment; monitor renal function and avoid in geriatric patients with renal impairment due to decreased creatinine clearance. Use lower end of dosing range and monitor acid-base status frequently.
Start at 250 mg daily; monitor renal function and adjust based on Cr Cl.
There is no FDA black box warning for tromethamine.
None
Monitor blood p H, p CO2, and electrolytes (especially potassium) during infusion,Use with caution in patients with renal impairment due to risk of accumulation,May cause respiratory depression, especially in patients with impaired renal function,Avoid extravasation due to tissue necrosis,Not recommended for neonatal use due to risk of hyperosmolality
Acute gout flares may occur initially,Hypersensitivity reactions including Stevens-Johnson syndrome,Renal impairment requires dose adjustment
Anuria or uremia,Chronic respiratory acidosis,Hypoglycemia,Hyperkalemia,Hypocalcemia,Known hypersensitivity to tromethamine
Hypersensitivity to probalan,Concurrent use with azathioprine or mercaptopurine
No known food interactions. However, electrolyte imbalances (e.g., hypokalemia) may be affected by dietary potassium intake; maintain a balanced diet per clinician advice.
High-purine foods (organ meats, anchovies, sardines) may increase uric acid; limit intake. Alcohol, especially beer, reduces uricosuric effect and increases uric acid; avoid or limit. Aspirin (anti-inflammatory doses) and some diuretics (thiazides) can reduce efficacy; avoid concurrent use.
Tromethamine is a parenteral alkalinizing agent used in metabolic acidosis. Animal reproduction studies have not been conducted. It is not known whether tromethamine can cause fetal harm when administered to a pregnant woman. Use during pregnancy only if clearly needed. Risk cannot be ruled out.
PROBALAN (probenecid) is not associated with major congenital malformations in human studies. However, dose-dependent neonatal toxicity (lactic acidosis) has been reported with third-trimester exposure due to inhibition of fetal renal clearance. Risk cannot be excluded; use only if maternal benefit outweighs potential fetal risk.
It is not known whether tromethamine is excreted in human milk. The M/P ratio is undetermined. Caution should be exercised when administered to a nursing woman.
Probenecid is excreted into breast milk in small amounts. M/P ratio is approximately 0.1. Infant exposure is negligible, but caution is advised due to potential for kernicterus in jaundiced infants. Consider discontinuing breastfeeding if infant is G6PD deficient.
No specific dosing adjustments are recommended for pregnancy. However, pharmacokinetic changes in pregnancy (increased plasma volume, altered renal function) may necessitate careful monitoring and titration based on clinical and laboratory response.
No standard dose adjustment recommended. Pregnancy increases renal clearance and volume of distribution, potentially reducing serum concentrations. Consider therapeutic drug monitoring if response inadequate. Avoid use in third trimester unless benefits outweigh risks.
Tromethamine (THAM) is an amino alcohol that acts as a proton acceptor, used to correct metabolic acidosis when sodium bicarbonate is contraindicated (e.g., hypernatremia, hypercapnia). It is preferred in patients with lactic acidosis or respiratory acidosis because it does not generate CO2. Monitor serum potassium closely as it can cause hypokalemia. Extravasation causes tissue necrosis; administer via central line if possible. Correct dosing is based on base deficit: m L of 0.3 M THAM = base deficit (m Eq/L) × weight (kg) × 1.1.
PROBALAN (probenecid) is a uricosuric agent used for chronic gout. Monitor serum uric acid levels; goal <6 mg/d L. Avoid in patients with creatinine clearance <50 m L/min or history of uric acid stones. Ensure adequate hydration (≥2 L/day) to prevent nephrolithiasis. Alkalinize urine (p H 6.5-7.0) with potassium citrate if needed. Contraindicated with aspirin >1 g/day due to decreased uricosuric effect. Not effective during acute gout attacks; initiate after inflammation subsides.
This medication is used to treat acidosis (too much acid in the blood).,It is given intravenously (IV) by your healthcare provider.,Report any signs of IV site reaction: pain, redness, swelling, or blistering.,You may need frequent blood tests to monitor your acid-base balance and potassium levels.,Tell your doctor if you have kidney disease or low blood potassium before treatment.
Take with food or milk to reduce gastrointestinal upset.,Drink at least 2 liters of water daily to prevent kidney stones.,Avoid aspirin or aspirin-containing products; use acetaminophen for pain.,Report rash, fever, or painful urination immediately.,May take several months to achieve full effect; do not stop suddenly.
"Methotrimeprazine may reduce the gastrointestinal absorption of tromethamine, an alkalinizing agent, leading to decreased systemic exposure and potentially diminished therapeutic efficacy. This interaction is hypothesized to occur via altered gastric pH or motility, though direct evidence is limited. Patients may experience reduced effectiveness of tromethamine in managing acid-base disorders."
"Tromethamine, an alkalinizing agent used to correct metabolic acidosis, can increase gastric pH, which may reduce the absorption of weakly acidic drugs like estrone sulfate. This altered gastrointestinal environment can decrease estrone sulfate bioavailability, potentially compromising its systemic effects for hormone replacement therapy. Clinically, this may lead to reduced efficacy of estrone sulfate, requiring dose adjustments or alternative administration routes."
"Tromethamine, an alkalinizing agent, can increase urinary pH, which enhances the renal excretion of sotalol, a class III antiarrhythmic that is primarily eliminated unchanged by the kidneys. This interaction may lead to reduced serum sotalol concentrations, potentially decreasing its therapeutic efficacy and increasing the risk of arrhythmia recurrence, particularly in patients with renal impairment or those requiring precise antiarrhythmic control."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TROMETHAMINE vs PROBALAN, answered by our medical review team.
TROMETHAMINE is a Alkalinizing Agent (Buffer) that works by Tromethamine is a proton acceptor that buffers hydrogen ions, correcting metabolic acidosis by increasing bicarbonate and base excess. It acts as a weak base with high buffering capacity.. PROBALAN is a Uricosuric Agent that works by Inhibits xanthine oxidase, reducing uric acid production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TROMETHAMINE and PROBALAN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TROMETHAMINE is: Intravenous: 1 M solution (3.6 g/30 m L) administered via central line; usual adult dose 300-500 mg/kg (0.27-0.45 g/kg) given over 1-2 hours; may be repeated based on blood gas monitoring.. The standard adult dose of PROBALAN is: 500 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TROMETHAMINE and PROBALAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TROMETHAMINE is classified as Category C. Tromethamine is a parenteral alkalinizing agent used in metabolic acidosis. Animal reproduction studies have not been conducted. It is not known whether tromethamine can cause feta. PROBALAN is classified as Category C. PROBALAN (probenecid) is not associated with major congenital malformations in human studies. However, dose-dependent neonatal toxicity (lactic acidosis) has been reported with thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.